Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mersana Therapeutics
Biotech
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
The biotech is laying off 55% of its employees and cutting back internal R&D work to focus on lead program emiltatug ledadotin.
Nick Paul Taylor
May 6, 2025 9:40am
It’s a wrap for Merck KGaA and Mersana’s 2014 ADC pact
Dec 22, 2023 10:37am
GSK loses its STING as part of phase 1 cleanout
Nov 1, 2023 6:38am
Mersana's phase 1 ADC cancer trial breaks free of FDA hold
Oct 31, 2023 1:21pm
CEPI's founding CEO to lead Wellcome—Chutes & Ladders
Oct 13, 2023 9:30am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
